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Abstract
Background: Clinical management of rectal cancer patients relies on pre-operative staging. Studies however continue 
to report moderate degrees of over/understaging as well as inter-observer variability. The aim of this study was to 
determine the sensitivity, specificity and accuracy of tumor size for predicting T and N stages in pre-operatively 
untreated rectal cancers.
Methods: We examined a test cohort of 418 well-documented patients with pre-operatively untreated rectal cancer 
admitted to the University Hospital of Basel between 1987 and 1996. Classification and regression tree (CART) and 
logistic regression analysis were carried out to determine the ability of tumor size to discriminate between early (pT1-2) 
and late (pT3-4) T stages and between node-negative (pN0) and node-positive (pN1-2) patients. Results were validated 
by an external patient cohort (n = 28).
Results: A tumor diameter threshold of 34 mm was identified from the test cohort resulting in a sensitivity and 
specificity for late T stage of 76.3%, and 67.4%, respectively and an odds ratio (OR) of 6.67 (95%CI:3.4-12.9). At a 
threshold value of 29 mm, sensitivity and specificity for node-positive disease were 94% and 15.5%, respectively with 
an OR of 3.02 (95%CI:1.5-6.1). Applying these threshold values to the validation cohort, sensitivity and specificity for T 
stage were 73.7% and 77.8% and for N stage 50% and 75%, respectively.
Conclusions: Tumor size at a threshold value of 34 mm is a reproducible predictive factor for late T stage in rectal 
cancers. Tumor size may help to complement clinical staging and further optimize the pre-operative management of 
patients with rectal cancer.
Background
C l i n i c a l  m a n a g e m e n t  o f  p a t i e n t s  w i t h  r e c t a l  c a n c e r
depends significantly on pre-operative staging. Parame-
ters such as cT and cN stage obtained by magnetic reso-
nance imaging (MRI), computed tomography (CT) or
endorectal ultrasonography (EUS) are crucial in selecting
patients for pre-operative neoadjuvant therapy [1,2].
According to the European Society of Medical Oncology
(ESMO), patients with T1-2, some early T3 and lymph
node-negative disease may benefit most from surgery
alone, whereas patients with more locally advanced
stages (most T3, some T4 and those with lymph node
positivity) are recommended for pre-operative radiother-
apy followed by total mesorectal excision (TME) with the
goal of decreasing local recurrence rates [3,4].
However, recent studies report variability in the accu-
racy of pre-operative staging of rectal cancer. All three
methods (CT, MRI and EUS) can lead to moderate rates
of over- or understaging of T and N stages compared to
histology in pre-operatively untreated patients [5-10].
Whereas EUS or CT seem to be more accurate for the
detection of early T1/T2 cancer, understaging with CT
has been described for T3 tumors in comparison to MRI
[10-13]. In contrary, lymph node positivity may be best
d e t e c t e d  b y  M R I ,  a l t h o u g h  i n t e r - o b s e r v e r  v a r i a b i l i t y
using this method has been described [14-19]. Overall,
clinical imaging appears to result in an overall accuracy of
65%-90% and is closely related to observer experience [1].
Taken together, detection of novel prognostic factors
capable of complementing clinical staging is warranted to
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identify patients in the pre-operative setting with locally
advanced disease.
We and other groups have suggested that protein bio-
markers in the pre-operative biopsy may help to identify
patients with poor survival who might be candidates for
neoadjuvant therapy [20]. Such biomarkers include the
epidermal growth factor receptor (EGFR) and vascular
endothelial growth factor (VEGF), among others [21-23].
To date, despite promising results, no single immunohis-
tochemical protein marker has been introduced into daily
practice. This may in large part be due to the lack of stan-
dardized scoring systems for evaluating immunohis-
tochemistry results.
The tumor diameter plays an integral part in cancer
staging in certain tumor types, such as stage I to III breast
cancer and gastric cancer [24]. In the latter group, tumor
size has been reported to be an independent prognostic
factor of both pT and pN stages [25-29]. In fact, the
strong link between tumor size, pT and pN stages has also
been used to provide evidence supporting the cause of
death of Emperor Napoleon Bonaparte from gastric can-
cer [30].
Only limited data have been published regarding the
role of tumor size in predicting T and N stages in
untreated rectal cancer patients. If an association could
be demonstrated, it would provide crucial information
for clinical staging. The aim of this study was to deter-
mine the sensitivity, specificity and accuracy of tumor
size for predicting T and N stages in rectal cancers. To
this end, we evaluated 418 patients with rectal cancers
who received no pre-operative therapy, therefore tumor
size and its predictive value was elaborated based on pT
and pN stages confirmed pathologically. Results were
subsequently validated by an external patient cohort.
Methods
Test Cohort
482 untreated, unselected rectal cancer patients admitted
to the University Hospital of Basel between 1987 and
1996 were initially included in this study. Haematoxylin
and eosin (H&E) stained slides were retrospectively col-
lected from the Institute of Pathology, University Hospi-
tal of Basel, the Institute of Clinical Pathology, Basel,
Switzerland and the Institute of Pathology, Stadtspital
Triemli, Zürich, Switzerland. Histopathological criteria
were reviewed by an experienced gastrointestinal pathol-
ogist and included tumor diameter, pT and pN classifica-
tion, grade of differentiation, histologic subtype, and the
presence of tumor invasion into vessels. Clinical data
including patient age at diagnosis, tumor location and fol-
low-up were obtained from patient records. Cancer-spe-
cific survival time was the main clinical endpoint of
interest. Censored observations included patients who
were alive at the last follow-up, died for reasons other
than colorectal cancer or were lost to follow-up. 5-year
cancer-specific survival rate was 57% (95%CI: 51-61).
Patient characteristics are summarized in Table 1. The
use of patient data has been approved by the local Ethics
Committee of the University of Basel, Switzerland.
External Validation Cohort
28 non-consecutive rectal cancer patients treated at the
4th Department of Surgery, University of Athens Medical
School were randomly selected from the archives of the
2nd Department of Pathology, University of Athens Med-
ical School (Attikon University Hospital), Greece.
Patients were treated between 2004 and 2006. All histo-
Table 1: Characteristics of rectal cancer patients in the test 
cohort (n = 418)
Clinco-pathological 
features
Frequency N (%)
Patient age at diagnosis 
(years)
Median (min-max) 69.0 (36-96)
Tumor size (mm) Median (min-max) 45.0 (12-100)
Gender Male 197 (47.1)
Female 221 (52.9)
Diagnosis Non-mucinous 18 (4.3)
Mucinous 400 (95.7)
pT classification pT1-2 119 (28.5)
pT3-4 299 (71.5)
pN classification pN0 226 (54.1)
pN1-2 192 (45.9)
Tumor grade G1-2 392 (94.2)
G3 24 (5.8)
Vascular invasion Absent 311 (74.8)
Present 105 (25.2)
Distant metastasis Absent 77 (90.6)
Present 8 (9.4)
Post-operative therapy None 66 (77.7)
Treated 19 (22.4)
Survival rate (5-years) 95%CI 56.9 (52-62)Zlobec et al. BMC Gastroenterology 2010, 10:61
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morphological data were reviewed from the correspond-
ing hematoxylin and eosin (H&E) stained slides, while
clinical data were obtained from corresponding reports.
Information included gender, age, tumor diameter, histo-
logical subtype, tumor location, pT stage, pN stage, pM
stage, vascular invasion and lymphatic invasion. 5-year
survival rate for the entire cohort was 67.6% (44-83).
Information on post-operative therapy was available for
all patients. Patient characteristics are summarized in
Table 2. The use of patient data has been approved by the
local Ethics Committee of the University of Athens,
Greece.
Statistical Analysis
To determine the most appropriate cut-off score for
tumor diameter and to allow optimal classification of
patients into pT1-2 and pT3-pT4 as well as pN0 and pN1-
2 stages, Classification and Regression Tree (CART) anal-
ysis was performed on the test group of 418 patients.
CART generates a clinical decision rule which can be
visualized as a "decision-tree". The computer-generated
algorithm uses a binary recursive process which splits the
data into the best possible combination of variables to
optimally classify patients into those with or without the
outcome. To measure the classification error as a func-
tion of tree size, 10-fold cross-validation experiments
w e r e  p e r f o r m e d .  F o r  e a c h  o f  t h o s e  e x p e r i m e n t s ,  d a t a
were randomly split into 10 smaller subsets. A backward
pruning method was used to choose the best number of
nodes from the original tree. Once the 10 trees are built,
their classification error rate as a function of tree size is
averaged. The tree size that produces the least amount of
misclassification is selected as the optimal tree. Simple
logistic regression analysis was performed in order to
determine the odds of having pT3-4 or pN1-2 with
tumors below or above the obtained cut-off score from
C A R T  a n a l y s i s .  O d d s  r a t i o s  ( O R )  a n d  9 5 %  c o n f i d e n c e
intervals (CI) were used to determine the effect of tumor
d i a m e t e r  o n  m o r e  a d v a n c e d  p T  o r  p N  c l a s s i f i c a t i o n .
Finally, receiver operating characteristic (ROC) curve
analysis and the area under the ROC curve (AUC) were
used to determine overall accuracy of tumor size on out-
come. The closer the AUC value is to 1.0 and the further
away from 0.5, the more tumor size discriminates
between pT and pN classification. Kaplan-Meier survival
curve and the log-rank test were used to evaluate survival
time differences in univariate setting. P-values <0.05 were
considered statistically significant.
Results
Test Cohort
T stage
Of the 482 patients initially included in our study, infor-
mation on tumor diameter, pT and pN stages was avail-
able in 418 cases. Using CART analysis, a tumor diameter
of 34 mm was found to be most useful for discriminating
between patients with early (pT1/pT2) and late (pT3/pT4)
T stage. In particular, of the 327 cases with >34 mm rectal
cancer, 80% (n = 261) had late T stage cancers. These
patients had a 6.67 (95%CI: 3.4-12.9) times greater odds
of pT3-4 lesions compared to those with ≤34 mm (Table
3). Moreover, 31/46 (67%) patients with ≤29 mm tumors
in diameter were pT1-pT2 (Figure 1). 45 patients had
tumors with a diameter of 29-34 mm. Classification of
these patients into early or late T stages was ambiguous
Table 2: Characteristics of rectal cancer patients in the 
validation cohort (n = 28)
Clinco-pathological 
features
Frequency N (%)
Patient age at diagnosis 
(years)
Median (min-max) 65 (38-82)
Tumor size (mm) Median (min-max) 40 (10-70)
Gender Male 13 (46.4)
Female 15 (53.6)
Diagnosis Non-mucinous 26 (92.9)
Mucinous 2 (7.1)
pT classification pT1-2 12 (42.9)
pT3-4 16 (57.1)
pN classification pN0 15 (53.6)
pN1-2 13 (46.4)
pM classification pM0 27 (96.4)
pM1 1 (3.6)
Tumor grade G1-2 18 (78.3)
G3 5 (21.7)
Vascular or lymphatic 
invasion
Absent 25 (89.3)
Present 3 (10.7)
Adjuvant therapy Absent 10 (35.7)
Present 18 (64.3)
Survival rate (5-years) 95%CI 67.6 (44-83)Zlobec et al. BMC Gastroenterology 2010, 10:61
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with 51% found to be early and 49% late T stage. Sensitiv-
ity and specificity of tumor size for pT3-4 using a cut-off
score of 34 mm were 76.3% and 67.4%, respectively, with
an overall diagnostic accuracy of 66%.
N stage
A tumor diameter of 29 mm was most discriminating
between node-negative (pN0) and node-positive (pN1-2)
patients. Of the 46 patients with ≤29 mm cancers, 76% (n
= 35) had node-negative and 24% node-positive disease.
These patients had an OR of 3.02 (95%CI: 1.5-6.1) indi-
cating that cases >29 mm in diameter had more than a 3-
fold greater odds of node-positivity compared to cancers
that were ≤29 mm. Only 7 patients had tumors exceeding
92.5 mm in size and 6/7 (85.7%) were node-positive. A
large subgroup of patients (n = 365) with tumor diame-
ters from 29 to 92.5 mm had a similar probability of being
classified as either node-negative (52%; n = 190) or node-
positive (48%, n = 175). Although highly sensitive for
pN1-2 stages, tumor size was significantly less specific for
pN0 cases (sensitivity and specificity for pN1-2 were
94.3% and 15.5%, respectively), while the overall diagnos-
tic accuracy was 55%.
Comparison of survival by T stage and tumor size
The predictive ability of a tumor diameter of 34 mm for
early and late T stages was validated using survival time.
In Figure 2, survival time differences between patients
with early and late pT stages are shown (p < 0.001). Simi-
lar differences were observed when compared to survival
time differences in patients with ≤34 or >34 mm tumor
sizes (p = 0.001).
External Validation Cohort
To validate these findings, a second independent cohort
of untreated rectal cancer patients was analyzed. Apply-
ing a cut-off of 34 mm to tumor size and classifying
patients in early or late T stages, the sensitivity, specific-
ity, and overall diagnostic accuracy for late T stage were
73.7%, 77.8% and 73%, respectively (Table 4). For pN clas-
sification, using a cut-off of 29 mm, sensitivity, specificity
and overall accuracy were 50%, 75% and 56%, respec-
tively. Thus, the high accuracy of tumor size in predicting
T stages and its moderate ability with respect to N stages
were reproduced in this second cohort.
Discussion and conclusions
The results of this study using test and validation cohorts
of more than 400 pre-operatively untreated rectal cancer
patients suggest that tumor size at a cut-off of 34 mm is
significantly related to pT stage. This indicates that tumor
size can be used to improve the assessment of pre-opera-
tive staging.
Precise pre-operative staging has a crucial role in plan-
ning treatment strategy in rectal cancer. Extensive studies
have compared the accuracy of different imaging modali-
ties to correctly stage rectal cancers pre-operatively.
These studies show that despite considerable improve-
ment in resolution of various imaging techniques, accu-
rate pre-operative staging remains challenging. For
example, differentiation between T2 and early T3 stages
is often difficult even with MRI due to desmoplastic reac-
tion around the tumor that mimics neoplastic tissue [31-
34]. Inability to identify lymph nodes containing micro-
metastases as well as size overlap between reactive nodes
and those containing metastases are other major chal-
lenges for all imaging modalities including high resolu-
tion MRI [33,35-37].
Previous reports have evaluated the association of
tumor size, prognosis, cancer recurrence and peri-rectal
lymph node involvement. Wolmark and colleagues found
that among patients with Dukes C colorectal tumors,
Table 3: Association of tumor diameter with pT and pN classifications in rectal cancer-test cohort (n = 418)
Frequency N (%) OR (95%CI) P-value AUC
≤ 34 mm >34 mm
pT classification pT1-2 31 (67.4) 88 (23.7) 6.67 (3.4-12.9) <0.001 0.66
pT3-4 15 (32.6) 284 (76.3)
≤ 29 mm >29 mm
pN classification pN0 35 (15.5) 11 (5.7) 3.02 (1.5-6.1) 0.002 0.55
pN1-2 191 (84.5) 181 (94.3)
OR: odds ratio. AUC: area under the ROC curve, illustrating discriminatory ability of tumor size for pT and pN classificationsZlobec et al. BMC Gastroenterology 2010, 10:61
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depth of penetration was related to tumor size and num-
ber of positive lymph nodes [38]. In a comprehensive
analysis, Cai and colleagues, reported an independent
predictive effect of tumor size along with pre-operative
CEA level and tumor differentiation for identifying
locally advanced rectal cancer [39]. In a series of 265 pT1
and pT2 colorectal cancer patients including 164 rectal
cancers, Chock and Law showed that tumor size was
associated with pT stage but not lymph node status [40].
A similar study by Rasheed et al on 303 patients with pT1
and pT2 rectal cancer revealed a direct correlation
between tumor size and depth of invasion but not lymph
node metastasis [41]. Kikuchi et al reported a direct asso-
ciation between tumor diameter and depth of invasion as
well as lack of a correlation between tumor size and
lymph node metastasis in 182 colorectal cancer cases
[42]. Using 10 mm as cut off, Matsuda et al showed that
depth of invasion but not node involvement was associ-
ated with tumor size [43]. Our study suggests for the first
time a tumor diameter threshold allowing reproducible
prediction of higher T stages (pT3-pT4) and worse sur-
vival. The results of this study are in line with most previ-
ous reports showing lack of accuracy for tumor size to
predict N stage [44-47]. The study of Zhang et al is
among the few reports demonstrating a direct association
between tumor size and nodal metastasis [48].
Our study is limited by the fact that it is a retrospective
analysis of rectal cancer patients. Additionally, since TME
was only introduced in Switzerland for the treatment of
rectal cancer in the summer of 1995, nearly all the
patients in this study did not undergo this surgical proce-
dure. Thirdly, the assessment of tumor deposits, as
required for accurate staging according to the most
recent 7th edition of the American Joint Committee on
Figure 1 Classification of rectal cancer patients (test cohort) into early and late T stages or into node-negative and node-positive disease 
based on tumor diameter using classification and regression tree analysis (CART). For the classification of patients by T stage, numbers in pa-
rentheses describe (the number of patients with early T, late T stage) followed by (percentage of patients with early T and late T stages). For the clas-
sification of patients by N stage, numbers in parentheses describe (the number of patients with node-negative, node-positive disease) followed by 
(percentage of patients with node-negative, node-positive disease).Zlobec et al. BMC Gastroenterology 2010, 10:61
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Cancer and International Union against Cancer Classifi-
cation (AJCC/UICC) were not evaluated in this series;
staging was performed according to the 6th edition of the
cancer staging manual. However, since this study was not
focused on prognosis of patients with rectal cancer but
rather on the predictive ability of tumor size on pT and
pN stage, the lack of information of these and other prog-
nostic factors only minimally affects the major results of
this study. In addition, this analysis benefits from a large
number of rectal cancer patients as well as the use of a
test and validation group. The results of the latter con-
firmed that the determined cut-off score of 34 mm leads
to similar prediction of advanced pT stage.
In conclusion, tumor size may help to determine the
best treatment option for rectal cancer patients. A tumor
size of >34 mm is highly related to more advanced pT
stages.
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